Innovation, experience, knowledge and transfer of skills are all enhanced when surrounded by people in similar industries. One of the greatest perks of locating here is the opportunity to network and collaborate with like-minded businesses.
Private medical facility specialising in the treatment of varicose veins and other venous conditions. With a strong background in research and innovation, we have been at the forefront of vein treatment developments over the last decade.
The Naked Pharmacy is Europe's first 100% Natural Pharmacy specialising in effective strength Food based supplements and natural medicines. Our own -branded products are available in both independent health stores and pharmacies and also online via our website.
The Centre is comprised of the NHS Supraregional Assay Service (SAS) Trace Element Laboratory which provides specialist pathology services for the measurement of trace metals and the Trace Element External Quality Assurance Scheme (TEQAS) which provides EQA services nationally and internationally.
Re:Cognition Health (RCH) is the leading independent UK provider of clinical services for cognitive disorders, providing unique, patient-centred, clinical pathways for early, accurate, diagnosis and management of cognitive impairment. RCH is recognised, globally, for its leading centres for final phase international clinical trials for individuals with MCI/Alzheimer’s disease.
Hygiena delivers rapid microbial detection, monitoring, and identification solutions to a wide range of industries, including food and beverage, healthcare, hospitality, pharmaceuticals, and personal care. Utilizing advanced technologies and patented designs, Hygiena provides industry-leading ATP monitoring systems, PCR-based pathogen detection and characterization systems, allergen tests, environmental collection devices, and more.
The HOX genes offer a novel therapeutic target with potential applicability across many cancer types. The Company’s scientific approach is based on the over expression and unique role of developmental HOX genes in tumour biology and pathogenesis. HOX Therapeutics has developed proprietary technology that disrupts specific or targeted HOX to co-factor binding making the previously intractable HOX biology druggable.
The HOX technology has potential applicability across many cancer types, offering a novel modality to develop therapeutics. Hox Therapeutics is initially focused on developing innovative therapies for brain cancer and prostate cancer, huge areas of major unmet medical need. It aims to take its lead asset HTL-001 to treat brain cancer into clinical development in 2019.